FRANKFURT, Germany — August 9, 2025 — Leads & Copy — Anbio Biotechnology has launched its Chikungunya IgM/IgG Rapid Test in response to recent outbreaks of Chikungunya fever. The test offers clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. Cases continue to rise across tropical and subtropical regions, making timely detection and differentiation from other arboviral infections like Dengue and Zika critical.
The test uses immunochromatographic technology for reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. Anbio is also advancing decentralized molecular diagnostics with its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care.
The AP-100 uses an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without nucleic acid extraction. The integrated design streamlines sample-to-result workflows, making it suited for deployment in centralized laboratories and decentralized, point-of-care environments. It delivers 15-minute PCR results from raw sample to answer; extraction-free workflow with no hazardous reagents; a compact 668g device for mobile or near-patient testing; broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV; and lab-comparable accuracy validated against mainstream PCR platforms.
Anbio is expanding its assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV). Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics.
Contact: connect@anbio.info
Source: Anbio Biotechnology
